Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
Bispecific (DLL3×CD3)
Tarlatamab
Imdelltra · Tarla
A DLL3×CD3 BiTE for small-cell lung cancer — cytokine release can drive pre-renal AKI.
ModerateBispecific T-cell engager (DLL3×CD3) · approved 2024
Extensive-stage small-cell lung cancer (relapsed/refractory)
Signature kidney injury
Prerenal / Hemodynamic AKI
Cytokine release syndrome is the dominant on-target toxicity — common (majority of patients in early studies), mostly low-grade, and mitigated by step-up/priming dosing and inpatient monitoring of initial doses. AKI is principally a downstream consequence of CRS (hypotension, fever, capillary leak, volume shifts) rather than a direct tubular toxin; renal-specific incidence is not separately well quantified.
Source: Paz-Ares et al., J Clin Oncol 2023 (DeLLphi-300)
Mechanism of kidney injury
Synapse-driven T-cell activation releases a surge of inflammatory cytokines (IL-6, IFN-γ, TNF-α) — the cytokine release syndrome. The resulting vasodilation, hypotension, capillary leak and fever cause renal hypoperfusion and pre-renal azotemia; if hypotension is severe or prolonged this progresses to ischemic acute tubular necrosis. By close analogy to other T-cell-redirecting therapies, cytokine-mediated podocyte/tubulointerstitial injury (and rarely collapsing glomerulopathy, reported with CAR-T and blinatumomab) is a theoretical additional mechanism. ICANS (neurotoxicity) may co-occur.
Clinical presentation
Fever and hypotension of CRS accompanied by a rising creatinine; pre-renal urine indices (low FeNa, concentrated urine) early, evolving to muddy-brown-cast ATN if perfusion is not restored. Tachycardia, hypoxia and elevated inflammatory markers/ferritin support CRS.
Onset
CRS typically within the first cycle, often after the first full (post-priming) doses; AKI tracks the CRS course.
Reversibility
Reversible
Anticancer mechanism
Bispecific T-cell engager (BiTE) with one arm binding DLL3 (highly expressed on small-cell lung cancer cells) and the other binding CD3 on T cells, forming an immunologic synapse that redirects polyclonal cytotoxic T cells to lyse tumor. Approved for relapsed/refractory extensive-stage small-cell lung cancer.
Management
Treat CRS promptly: IV fluids for hypotension, antipyretics, tocilizumab (IL-6 receptor blockade) and corticosteroids per grade-based algorithms; restore perfusion early. Provide supportive AKI care and renal replacement therapy if severe. Most CRS-mediated AKI is reversible once hemodynamics normalize.
Risk factors
- Higher CRS grade
- Volume depletion at dosing
- Pre-existing CKD
- Concurrent nephrotoxins
- High disease burden
Prevention
- Step-up/priming dosing and protocol-defined monitoring per label
- Adequate hydration before dosing
- Prompt CRS recognition and treatment
- Avoid nephrotoxins during the CRS window
Note · Kidney injury is CRS-mediated and largely preventable with priming-dose strategy and prompt CRS management; tarlatamab is not a primary nephrotoxin. Inpatient monitoring of the first doses is the key safeguard.
Clinical depth
Renal dose adjustment
No established renal dose adjustment (T-cell engager, not renally cleared); dosing is by step-up schedule. The renal-relevant action is hemodynamic support during CRS, not dose modification for GFR.
Dialyzability & ESKD dosing
Bispecific antibody construct — not dialyzable and not renally eliminated; no ESKD dose change expected. Renal replacement therapy is for CRS-driven AKI, not drug clearance.
Differential diagnosis
CRS-driven pre-renal/ischemic ATN (fever, hypotension, high ferritin) vs sepsis-related AKI vs tumor lysis vs nephrotoxin exposure; persistent nephrotic-range proteinuria would raise the rare possibility of cytokine-mediated podocytopathy (CAR-T/blinatumomab precedent) and warrant biopsy.
Monitoring
- Vital signs/temperature and oxygenation intensively around initial doses (CRS watch)
- Serum creatinine and electrolytes through the CRS window
- Inflammatory markers (ferritin, CRP) if CRS suspected
- Neuro checks for ICANS
Key trials & series
- DeLLphi-300 (Paz-Ares JCO 2023) first-in-class phase I
- DeLLphi-301 phase II (registrational)
- Sands Cancer 2025 practical CRS-management guidance
Clinical pearls
- The AKI is CRS hemodynamics, not a tubular poison — fix the blood pressure and fever and the kidney follows.
- Priming/step-up dosing with inpatient monitoring of first doses is the single most important renal-protective measure.
- Tocilizumab plus fluids and steroids per CRS grade restores perfusion and reverses most AKI.
- Watch for the rare cytokine-driven collapsing glomerulopathy seen with related T-cell redirectors if heavy proteinuria appears.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
Prerenal / Hemodynamic AKIAcute Tubular Necrosis
Beyond the kidney
Class-level context for the major non-renal toxicities of bispecific (dll3×cd3)s.
Immune / Infusion
CRS, infusion reactions, irAEs, anaphylaxis
- Cytokine release syndrome
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
- ICANS / neurotoxicity
Hematologic
Cytopenias, thrombosis, TMA
- Cytopenias, hypogammaglobulinemia
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkTarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.Paz-Ares L et al. · J Clin Oncol 2023 · PMID 36689692First-in-class data establishing CRS as the principal toxicity driving downstream organ effects.PMIDPractical management of adverse events in patients receiving tarlatamab, a DLL3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer.Sands JM et al. · Cancer 2025 · PMID 39876075Practical guidance on recognizing and managing CRS and related complications, including supportive care relevant to renal perfusion.PMIDCollapsing Focal Segmental Glomerulosclerosis and Acute Kidney Injury Associated With Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Case Report.Acharya R et al. · Kidney Med 2021 · PMID 34939018T-cell-redirecting therapy (CAR-T and blinatumomab) causing CRS-associated AKI and collapsing glomerulopathy — precedent for tarlatamab's class mechanism.PMIDRenal Side Effects of Novel Molecular Targeted Oncologic Agents.Fenoglio R et al. · G Ital Nefrol 2023 · PMID 38007829Onconephrology overview of renal injury from novel immuno/targeted agents and the role of biopsy when AKI develops.PMIDConventional Chemotherapy Nephrotoxicity.Gupta S et al. · Adv Chronic Kidney Dis 2021 · PMID 35190107Onconephrology reference for pre-renal/ischemic ATN mechanisms relevant to CRS-driven hypotension.PMIDCurrent Trends in Anti-Cancer Molecular Targeted Therapies: Renal Complications and Their Histological Features.Tonooka A et al. · J Nippon Med Sch 2021 · PMID 34840210Histopathologic framing of immune/targeted-therapy renal complications relevant to T-cell-engager toxicity.
Related agents
Other agents sharing the same signature kidney injury.